Investors signal concern that the expiring federal EV tax credit created a 'pull-forward' of demand, raising questions about future growth.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Stock soars as government backing for domestic lithium production and positive sector sentiment fuel investor optimism.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Company forecasts a $710 million revenue hit from expanded U.S. export restrictions, impacting its significant business in the Chinese market.
The video platform's collaboration with the AI search company aims to enhance content discovery and user experience.
Needham reiterates a 'Buy' rating with a $1,950 price target, fueling investor optimism despite significant insider sales.